{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:14:27Z","timestamp":1772190867735,"version":"3.50.1"},"reference-count":28,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2025,11,12]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>\n                    This systematic review and meta-analysis aimed to investigate the necessity of histamine-2 antagonists (H2As) in paclitaxel premedication protocols, particularly in preventing hypersensitivity reactions (HSRs). The research question addressed whether the inclusion of H2As significantly reduces the incidence of HSRs associated with paclitaxel treatment. A comprehensive literature search of MEDLINE, Cochrane and Web of Science databases was conducted to identify studies on prophylactic H2As for paclitaxel-induced HSRs up to December 2023. Studies were included based on predefined criteria, including adult patients with cancer receiving paclitaxel infusions. Quality of included studies was evaluated using the Risk Of Bias In Non-randomised Studies\u2013of Interventions tool and results were generated through a random effects statistical model. Six studies meeting the inclusion criteria were included in the meta-analysis. The analysis revealed no statistically significant difference in the incidence of grade III or higher HSRs (risk ratio, RR 1.04, 95%\u2009CI 0.65 to 1.67) or all-grade HSRs (RR 1.40, 95%\u2009CI 0.82 to 2.39) between patients receiving H2As as part of their premedication protocol and those without H2A blockade. Minimal heterogeneity was observed for grade III reactions (I\u00b2=0.0%, p=0.669), while high heterogeneity was noted for all-grade reactions (I\u00b2=73.4%, p=0.002). Subgroup analysis showed minimal heterogeneity with all-grade reactions once prospective studies were excluded (I\n                    <jats:sup>2<\/jats:sup>\n                    =0.0%, p=0.689). This meta-analysis supports the safe omission of H2As, particularly ranitidine, from paclitaxel premedication protocols without compromising patient safety in terms of HSRs.\n                  <\/jats:p>","DOI":"10.1136\/spcare-2024-005228","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:13:42Z","timestamp":1765278822000},"page":"262-270","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["H2-antagonists in paclitaxel premedication: systematic review and meta-analysis"],"prefix":"10.1136","volume":"16","author":[{"given":"Mohammed Yahya","family":"AlZahrani","sequence":"first","affiliation":[{"name":"College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"KAIMRC, Riyadh, Saudi Arabia"},{"name":"Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7229-9474","authenticated-orcid":false,"given":"Maha","family":"AlDoughaim","sequence":"additional","affiliation":[{"name":"College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"KAIMRC, Riyadh, Saudi Arabia"},{"name":"Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"AlSuhebany","sequence":"additional","affiliation":[{"name":"College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"KAIMRC, Riyadh, Saudi Arabia"},{"name":"Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulmajeed","family":"AlShehri","sequence":"additional","affiliation":[{"name":"College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"KAIMRC, Riyadh, Saudi Arabia"},{"name":"Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majed","family":"AlYami","sequence":"additional","affiliation":[{"name":"College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"KAIMRC, Riyadh, Saudi Arabia"},{"name":"Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AlJawharah","family":"AlEnezi","sequence":"additional","affiliation":[{"name":"College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"KAIMRC, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"Badawoud","sequence":"additional","affiliation":[{"name":"Princess Nora bint Abdul Rahman University, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"2026022702201311000_16.2.262.1","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1111\/bcp.15363","article-title":"Histamine-2 (H2) antagonists can be safely removed from standard paclitaxel premedication regimens","volume":"88","author":"Foreman","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026022702201311000_16.2.262.2","unstructured":"\"Lexi-drugs\u00ae (database on the internet). Paclitaxel Lexi-Comp Inc; 2023."},{"key":"2026022702201311000_16.2.262.3","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1097\/CM9.0000000000001562","article-title":"Assessing taxane-associated adverse events using the FDA adverse event reporting system database","volume":"134","author":"Lao","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"2026022702201311000_16.2.262.4","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.2147\/DDDT.S88023","article-title":"Albumin-bound paclitaxel in solid tumors: clinical development and future directions","volume":"9","author":"Kundranda","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2026022702201311000_16.2.262.5","unstructured":"Bristol-Meyers Squibb . Taxol (paclitaxel) prescribing information. 2020."},{"key":"2026022702201311000_16.2.262.6","doi-asserted-by":"crossref","first-page":"x313","DOI":"10.1093\/annonc\/mds314","article-title":"Prevention and handling of acute allergic and infusion reactions in oncology","volume":"23 Suppl 10","author":"Joerger","year":"2012","journal-title":"Ann Oncol"},{"key":"2026022702201311000_16.2.262.7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1990.8.7.1263"},{"key":"2026022702201311000_16.2.262.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.11.047"},{"key":"2026022702201311000_16.2.262.9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","article-title":"Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center","volume":"18","author":"Markman","year":"2000","journal-title":"J Clin Oncol"},{"key":"2026022702201311000_16.2.262.10","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1038\/s41416-021-01313-0","article-title":"The added value of H2 antagonists in premedication regimens during paclitaxel treatment","volume":"124","author":"Cox","year":"2021","journal-title":"Br J Cancer"},{"key":"2026022702201311000_16.2.262.11","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215589980"},{"key":"2026022702201311000_16.2.262.12","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00228-023-03536-x","article-title":"Impact of histamine-2 antagonist shortage on the incidence of hypersensitivity reactions to paclitaxel: a reconsideration of premedication protocols in France (PACLIREACT Study)","volume":"79","author":"Strobbe","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"2026022702201311000_16.2.262.13","first-page":"428","article-title":"Management of Hypersensitivity Reactions to Carboplatin and Paclitaxel in an Outpatient Oncology Infusion Center: A 5-Year Review","volume":"2","author":"Banerji","year":"2014","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"key":"2026022702201311000_16.2.262.14","first-page":"514","article-title":"Hypersenzitivn\u00ed reakce po pod\u00e1n\u00ed karboplatiny a paklitaxelu - na\u0161e p\u011btilet\u00e9 zku\u0161enosti [Hypersensitivity reactions to carboplatin and paclitaxel - our five-years experiences]","volume":"78","author":"Rez\u00e1\u010d","year":"2013","journal-title":"Ceska Gynekol"},{"key":"2026022702201311000_16.2.262.15","doi-asserted-by":"publisher","DOI":"10.2174\/1874306400903010123"},{"key":"2026022702201311000_16.2.262.16","unstructured":"National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE),\". Version 5.0. 2017."},{"key":"2026022702201311000_16.2.262.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026022702201311000_16.2.262.18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jppr.1768","article-title":"Is the use of ranitidine required as a pre\u2010medication to prevent hypersensitivity reactions to paclitaxel?","volume":"52","author":"Ryan","year":"2022","journal-title":"J Pharm Pract Res"},{"key":"2026022702201311000_16.2.262.19","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.985","article-title":"Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: A retrospective cohort study","volume":"10","author":"Haine","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"2026022702201311000_16.2.262.20","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.35006","article-title":"The utility of H2 receptor antagonists in preventing infusion-related reactions to paclitaxel chemotherapy","volume":"129","author":"Tsang","year":"2023","journal-title":"Cancer"},{"key":"2026022702201311000_16.2.262.21","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.31557\/APJCP.2022.23.4.1331","article-title":"Efficacy of Premedication Protocol without Ranitidine for Taxane Regimen: A Multicenter Non-Randomized Historical Controlled Study","volume":"23","author":"Chantharakhit","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"2026022702201311000_16.2.262.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504133321507"},{"key":"2026022702201311000_16.2.262.23","doi-asserted-by":"crossref","first-page":"iv100","DOI":"10.1093\/annonc\/mdx216","article-title":"Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines","volume":"28","author":"Rosell\u00f3","year":"2017","journal-title":"Ann Oncol"},{"key":"2026022702201311000_16.2.262.24","unstructured":"FDA requests removal of all ranitidine products (zantac) from the market. 2024."},{"key":"2026022702201311000_16.2.262.25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043886","article-title":"Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions","volume":"24","author":"Galateanu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026022702201311000_16.2.262.26","first-page":"4475","article-title":"Is antihistaminergic H2 really useful in prevention of hypersensitivity induced by paclitaxel?","volume":"24","author":"Slimano","year":"2016","journal-title":"Support Care Cancer"},{"key":"2026022702201311000_16.2.262.27","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.2RU1116-474R"},{"key":"2026022702201311000_16.2.262.28","doi-asserted-by":"crossref","first-page":"9405","DOI":"10.1038\/s41598-021-88829-w","article-title":"Histamine receptor 2 blockade selectively impacts B and T cells in healthy subjects","volume":"11","author":"Meghnem","year":"2021","journal-title":"Sci Rep"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2024-005228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:22:07Z","timestamp":1772187727000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2024-005228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,27]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/spcare-2024-005228"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2024-005228","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]}}}